FDA accepts Bristol Myers Squibb’s new drug application for iberdomide

2026-02-25 01:27:37

Abstract generation in progress

The FDA has accepted Bristol Myers Squibb’s New Drug Application for iberdomide in combination with daratumumab and dexamethasone for patients with relapsed or refractory multiple myeloma. The drug has been granted Breakthrough Therapy Designation and Priority Review, with a target action date of August 17, 2026. This application is based on data from the Phase 3 EXCALIBER-RRMM study.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.